Learning outcomes
By the end of this lesson you should be able to: distinguish absorption, distribution, metabolism and excretion; define bioavailability and explain the first-pass effect and why it changes with route; describe the factors that determine the volume of distribution and what a large or small volume implies about a drug; explain protein binding, the blood-brain barrier and placental transfer; and predict how a drug's physical properties determine where it ends up in the body.
Prerequisites
Lessons 1-2, and from PHYS 101 the mechanisms of membrane transport. Pharmacokinetics is physiology applied to a foreign molecule: it crosses membranes by the same rules.
The big idea
A useful abbreviation is ADME: absorption, distribution, metabolism, excretion. Each stage is a fate — a point at which the drug may be slowed, diverted or destroyed — and a drug's clinical behaviour is the net result of all four. A drug given into the gut must survive the stomach, cross the gut wall, cross the liver, survive metabolism, and then distribute to the tissue where it acts; only then can it bind the receptor you studied in the last lesson.
Absorption and routes
| Route | Absorption characteristics | Clinical note |
|---|---|---|
| Intravenous | Complete, immediate, and every molecule reaches the circulation | Required when a fast and predictable effect is needed, or when the gut cannot be used |
| Oral | Through the gut wall, then through the liver before the general circulation | The default: easy, but the first-pass effect and the gut's absorption limit both apply |
| Subcutaneous, intramuscular | Absorbed from the tissue, slowly and predictably | Depot preparations (insulin, depot antipsychotics, hormonal implants) rely on this |
| Sublingual, buccal | Absorbed directly into the venous drainage of the head, bypassing the liver | Nitrate spray, sublingual buprenorphine — where rapid effect or first-pass avoidance matters |
| Rectal | Partly absorbed directly, partly through the portal circulation | Useful when vomiting or swallowing is not possible, and in children |
| Topical, inhaled, transdermal | Local delivery, with limited systemic absorption unless designed otherwise | Transdermal patches produce a steady plasma concentration without peaks |
Bioavailability is the fraction of the administered dose that reaches the systemic circulation unchanged, and it is the parameter that differs most between routes. It is 100 per cent by the intravenous route and lower by the others. The oral route has two sources of loss: incomplete absorption from the gut, and metabolism in the gut wall and the liver before the drug reaches the general circulation. Once first-pass metabolism is saturated — which is why oral and intravenous doses of a propranolol, for instance, differ by a factor of several — the relationship between dose and blood level becomes non-linear and increasingly difficult to predict.
NoteThe first-pass effect is why some drugs cannot be given orally at all: nitroglycerin and lignocaine are metabolised so extensively in the liver that the oral route delivers almost nothing to the general circulation. Sublingual nitroglycerin bypasses it and works within minutes.
Worked example: what a volume of distribution tells you
If a 70 kg adult has 5 litres of blood and a drug distributes only into the blood, its volume of distribution is about 5 litres — the volume of the blood itself. If it also distributes into the extracellular fluid of 14 litres, its volume is about 14 litres. If it is lipophilic and distributes into total body water of about 42 litres, its volume is about 42 litres. And a drug that binds fat, such as a benzodiazepine or digoxin, may have a volume of 200 to 500 litres — larger than the body — because the plasma concentration is low relative to the total amount in the body.
| Volume of distribution | Interpretation | Clinical example |
|---|---|---|
| Small (about 3-5 litres) | Confined to the blood and the extracellular fluid | Heparin, which is a large molecule that stays in the circulation |
| Moderate (about 15-40 litres) | Distributes to body water | Lithium, alcohol, aminoglycosides such as gentamicin |
| Very large (hundreds of litres) | Distributes into fat or is heavily protein-bound, so plasma concentration is low | Amiodarone, digoxin, the benzodiazepines |
The value is used for one purpose clinically: calculating a loading dose. If a drug distributes into a very large volume, a large loading dose is needed to fill it — which is why digoxin needs a loading dose of about 500 to 1000 micrograms to fill its enormous volume, while a maintenance dose is small because elimination is slow. And a drug with a very large volume is removed by dialysis poorly, because the drug is not in the blood where the machine can reach it.
A lipophilic drug is ingested by a patient with a large body fat mass. Would you expect its volume of distribution to be large or small, and why?
Common mistakes
Watch outSaying bioavailability is different by the intravenous route because of the gut. It is 100 per cent intravenously by definition — the whole dose enters the circulation. The gut wall and liver only matter for the enteral routes.
Watch outSaying the volume of distribution is always a real anatomical compartment. It is a ratio, and for a drug bound to fat it can be many hundreds of litres — a real number, but not a real volume.
Watch outSaying a drug must cross the blood-brain barrier to act in the brain. It must, if its site of action is neural — but some central effects come from peripheral receptors (for instance, hypotension from a peripheral vasodilator causing a synchronised reflex).
Check your understanding
What is the first-pass effect, and why does it change the oral dose needed?
Why is digoxin given with a loading dose and a maintenance dose, and how does the volume of distribution decide the loading dose?
What limits drug transfer across the blood-brain barrier?
Multiple choice
What is the defining characteristic of a sublingual dose of nitroglycerin?
A drug has a volume of distribution of about 400 litres in a 70 kg adult. What does that imply?
Which statement about protein binding of drugs is correct?
Which is correct about the first-pass effect?
Which factor most favours passage of a drug across the blood-brain barrier?
Summary and next
Pharmacokinetics has four stages: absorption, distribution, metabolism and excretion. The route decides bioavailability, and the oral route suffers a first-pass loss in the gut wall and liver. The volume of distribution is a conceptual volume that tells you where a drug lives and therefore how big a loading dose it needs. Protein binding restricts a drug to the free fraction, and the blood-brain barrier restricts the drugs that reach the brain to the small, lipid-soluble and unbound. Each of these stages is a point at which the body can reduce or redirect the drug — and each is exploited in drug design to make the receptor you want see the drug you want.
Next: metabolism and excretion. You will meet the cytochrome P450 enzymes that make drugs soluble and eliminate them, the induction and inhibition interactions that make prescribing complicated, and the principle of half-life and steady state.